Niall Ashfield investigates how cancer cells develop resistance to treatment. By recreating drug resistance in laboratory-grown cancer cells, his research examines the cellular changes that allow tumours to survive therapy. Identifying vulnerabilities in resistant cells could reveal alternative treatments, improve patient outcomes and support collaborations with pharmaceutical companies worldwide.
Year
2024
Summary
Organisation
Year
2025
Summary
This research develops pH-responsive biomaterials to deliver chemotherapy directly to glioblastoma cells in the brain. By releasing drugs in the presence of cancer while remaining closed around healthy tissue, the approach aims to improve treatment effectiveness, reduce harmful side effects, and ultimately enhance patients’ quality of life and survival.
Organisation
Year
2026
Summary
This research develops nanoscale “smart package” delivery systems for PROTAC cancer drugs. Antibody nanogel conjugates selectively target cancer cells, enter them, and release therapeutic molecules while minimizing exposure to healthy tissue. The approach improves delivery efficiency and aims to reduce the severe side effects that often limit cancer treatment.
Organisation